Cytokine-activated degradation of inhibitory κB protein α is inhibited by the short-chain fatty acid butyrate

International Journal of Colorectal Disease

Volumn 16, Issue 4, 2001, Pages 195-201

  Luhrs H ^a   Gerke, T ^a   Schauber, J ^a   Dusel, G ^a   Melcher, R ^a   Scheppach, W ^a   Menzel, T ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

Butyrate; I B ; Nuclear factor B; Tumor necrosis factor

Indexed keywords

BUTYRIC ACID; CYTOKINE; I KAPPA B; I KAPPA B ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; POLYCLONAL ANTIBODY; RECOMBINANT TUMOR NECROSIS FACTOR ALPHA; SHORT CHAIN FATTY ACID; SYNAPTOTAGMIN; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

ADENOCARCINOMA; ANAEROBIC METABOLISM; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CARCINOMA CELL; CLINICAL TRIAL; COLON; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOPLASM; DRUG MECHANISM; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; PRIORITY JOURNAL; ULCERATIVE COLITIS; WESTERN BLOTTING;

ADENOCARCINOMA; BLOTTING, WESTERN; BUTYRATES; CELL NUCLEUS; CYTOKINES; DNA-BINDING PROTEINS; FLUORESCENT ANTIBODY TECHNIQUE; HELA CELLS; HUMANS; I-KAPPA B PROTEINS; NF-KAPPA B; PHOSPHORYLATION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0034926541     PISSN: 01791958     EISSN: None     Source Type: Journal    
DOI: 10.1007/s003840100295     Document Type: Article

References (47)

1. Clinical patterns, natural history, and progression of ulcerative colitis. A long-term follow-up of 1116 patients
2. Inflammatory bowel disease. I. Nature and pathogenesis
3. Nature of the tissue reaction in ulcerative colitis. Light and electron microscopic findings
4. Occurrence, absorption and metabolism of short chain fatty acids in the digestive tract of mammals
5. Role of anaerobic bacteria in the metabolic welfare of the colonic mucosa in man
6. The colonic epithelium in ulcerative colitis: An energy-deficiency disease?
7. Diversion colitis: A nutritional deficiency syndrome?
8. The starved colon-diminished mucosal nutrition, diminished absorption, and colitis
9. Effect of butyrate enemas on the colonic mucosa in distal ulcerative colitis
10. Short-chain fatty acid enemas: A cost-effective alternative in the treatment of nonspecific proctosigmoiditis
11. Short-chain fatty acid topical treatment in distal ulcerative colitis
12. Rectal irrigation with short-chain fatty acids for distal ulcerative colitis. Preliminary report
13. Treatment of refractory distal ulcerative colitis with short chain fatty acid enemas
14. Treatment of refractory ulcerative proctosigmoiditis with butyrate enemas
15. Topical treatment of refractory distal ulcerative colitis with 5-ASA and sodium butyrate
16. Treatment of diversion colitis with short-chain-fatty acid irrigation
17. Short chain fatty acids are effective in short-term treatment of chronic radiation proctitis: Randomized, double-blind, controlled trial
18. Butyrate, mesalamine, and factor XIII in experimental colitis in the rat: Effects on transglutaminase activity
19. Stimulation of intestinal mucosal growth with intracolonic infusion of short-chain fatty acids
20. Effect of volatile fatty acids on blood flow and oxygen uptake by the dog colon
21. Short chain fatty acids dilate isolated human colonic resistance arteries
22. NF-kappa B: Ten years after
23. Structure, regulation and function of NF-kappa B
24. TNF activates NF-kappa B by phosphatidylcholine-specific phospholipase C-induced "acidic" sphingomyelin breakdown
25. Tumor necrosis factor and interleukin-1 lead to phosphorylation and loss of I kappa B alpha: A mechanism for NF-kappa B activation
26. Recombinant IkappaB kinases alpha and beta are direct kinases of Ikappa Balpha
27. The IkappaB kinase complex (IKK) contains two kinase subunits, IKKalpha and IKKbeta, necessary for IkappaB phosphorylation and NF-kappaB activation
28. IKK-1 and IKK-2: Cytokine-activated IkappaB kinases essential for NF-kappaB activation
29. Coordinate regulation of IkappaB kinases by mitogen-activated protein kinase kinase kinase 1 and NF-kappaB-inducing kinase
30. Mitogen-activated protein kinase/ERK kinase kinases 2 and 3 activate nuclear factor-kappaB through IkappaB kinase-alpha and IkappaB kinase-beta
31. Control of I kappa B-alpha proteolysis by site-specific, signal-induced phosphorylation
32. Inhibition of interleukin-1-stimulated NF-kappaB RelA/p65 phosphorylation by mesalamine is accompanied by decreased transcriptional activity
33. The luminal short-chain fatty acid butyrate modulates NF-kappaB activity in a human colonic epithelial cell line
34. Biochemical and morphological differentiation of the human colonic epithelial cell line SW620 in the presence of dimethylsulfoxide
35. Characterization and quantitation of NF-kappaB nuclear translocation induced by interleukin-1 and tumor necrosis factor-alpha. Development and use of high capacity fluorescence cytometric system
36. Tumor necrosis factor induces lipopolysaccharide tolerance in a human adenocarcinoma cell line mainly through the TNF p55 receptor
37. Colonic epithelial cell lines as a source of interleukin-8: Simulation by inflammatory cytokines and bacterial lipopolysaccharide
38. Local administration of antisense phosphorothioate oligonucleotides to the p65 subunit of NF-kappa B abrogates established experimental colitis in mice
39. Nuclear factor kappaB is activated in macrophages and epithelial cells of inflamed intestinal mucosa
40. Effects of steroid treatment on activation of nuclear factor kappaB in patients with inflammatory bowel disease
41. Immunosuppression by glucocorticoids: Inhibition of NF-kappa B activity through induction of I kappa B synthesis
42. Role of transcriptional activation of I kappa B alpha in mediation of immunosuppression by glucocorticoids
43. Inhibition of NF-kappa B by sodium salicylate and aspirin
44. Salicylates inhibit I kappa B-alpha phosphorylation, endothelial-leukocyte adhesion molecule expression, and neutrophil transmigration
45. Butyrate modulates the production of TNF-alpha in Crohn's disease
46. Sulfasalazine: A potent and specific inhibitor of nuclear factor kappa B
47. Activation of p38 mitogen-activated protein kinase by sodium salicylate leads to inhibition of tumor necrosis factor-induced IkappaB alpha phosphorylation and degradation